Circulating CD14+HLA-DRlo/− monocytic MDSCs as an immune suppressive subset have potential clinical relevance for epithelial ovarian cancer progression [50] and HCC patients treated with trans-arterial radioembolization [65]. This evidence concerns the gene CD14 and ovarian carcinoma.